15-min delayed · Aug 26, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Aytu BioScience Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $7.00 to $14.50 (about 2.1x), a sign of real disagreement on valuation. The average target of $10.75 sits 369% above the current $2.29. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 2 over recent months. On the fundamentals, the Street sees revenue growth near -18% this year and 31% next, consensus EPS building from about $-0.02 next quarter toward $-0.07 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Strong Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Aytu BioScience Inc.
As of Aug, 2 of 2 firms rate AYTU a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
AYTU EPS & revenue forecast
EPS · NEXT QUARTER
$-0.02
Range $-0.02 – $-0.02 · 1 analysts · -79% YoY
Next period, 1 analysts expect Aytu BioScience Inc to earn $-0.02 a share (range $-0.02 – $-0.02), versus $-0.09 a year earlier. Full-year consensus is $-1.14, growing to $-0.07 the year after.
REVENUE · NEXT QUARTER
$17.2M
Range $17.2M – $17.2M · 1 analysts · +24% YoY
Revenue is expected to reach $17.2M (range $17.2M – $17.2M), +24.0% year-over-year., rising to $70.6M next year.
Top analysts covering Aytu BioScience Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AYTU.
#1
TF
Thomas Flaten
Lake Street · Rank #229
Buy
$7.00+205.7% to target
Overall win rate
40%
+ Follow
#2
Edward Woo
Ascendiant Capital · Rank #419
Buy
$14.50+533.2% to target
Overall win rate
25%
+ Follow
#3
NR
Naz Rahman
Maxim Group
Buy
$7.00+205.7% to target
Coverage
—
+ Follow
#4
EW
Edward Woo
Ascendiant
Buy
$14.00+511.4% to target
Coverage
—
+ Follow
AYTU stock forecast FAQ
What is AYTU's average 12-month price target?+
The 2 analysts with a live target average $10.75 for Aytu BioScience Inc over the next 12 months, ranging from a $14.50 high to a $7.00 low.
Is AYTU stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for AYTU?+
The Street-high target is $14.50 (Ascendiant Capital), and the Street-low is $7.00 (Maxim Group). The average of all 2 active targets is $10.75.
How many Wall Street analysts cover AYTU?+
2 analysts have an active rating on Aytu BioScience Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering AYTU?+
Among analysts who currently cover AYTU, Thomas Flaten of Lake Street has the strongest overall Quantellect track record (Rank #229). Their current call is Buy with a $7.00 target.
What is Aytu BioScience Inc's projected EPS for next quarter?+
The consensus estimate is $-0.02 per share (range $-0.02 – $-0.02) across 1 analysts. Full-year EPS is projected at $-1.14, rising to $-0.07 the following year.
How much revenue is Aytu BioScience Inc expected to report next quarter?+
Consensus revenue is $17.2M (range $17.2M – $17.2M). Full-year revenue is projected at —, growing to $70.6M next year.
Have analysts been upgrading or downgrading AYTU lately?+
As of Aug, 2 of 2 firms rate AYTU a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AYTU calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
